Current / Ongoing Studies Updated June 2021
| No | Study Name/Phase | Type | Sponsor | Population (Gender/Age) | Enrolled / (Target if still enrolling) | Period | |
| 1 | HVTN 702/Phase IIb | HIV Vaccine | HVTN | ♂/♀18-35 yrs | 483 | 2016 – 2021 | |
| 2 | HVTN 705/Phase IIb | HIV Vaccine | Janssen/HVTN | ♀18-35 yrs | 144 | 2018 – 2021 | |
| 3 | NC008/Phase IIc | TB Treatment | TB Alliance | ♂/♀≥18 | 33 | 2018 – 2020 | |
| 4 | PrEPARE Study/PrEP Rollout | PrEP | RTI | ♀16-24 yrs | n/a | 2019 – 2021 | |
| 5 | EPI RSV | RSV study | GSK | ♀ 18-45 | 100 | 2019 – 2020 | |
| 6 | R01 AI147681 KHARITUWE TB MIGRATION STUDY | TB Tracing | John Hopkins University | ♂/♀ 0-99 yrs | target 7200 | 2020 – 2025 | |
| 7 | NN9924-4309 (Pioneer 12) | Diabetes (China) | Novo Nordisk | ♂+♀ ≥18 | 2 | 2020 – 2022 | |
| 8 | ChAdOx1 nCoV-19 | Covid Vaccine | Bill & Melinda Gates and SAMRC | ♂+♀
18-65 |
417 | 2020 – 2021 | |
| 9 | C3671008 | RSV Vaccine | Pfizer | ♀ ≥18 and ≤49 | target 120 | 2020 – 2023 | |
| 10 | 2019nCoV-501_Vaccine_Study | Covid Vaccine | Novavax | ♂+♀ 18-64 | 324 | 2020 – 2021 | |
| 11 | VAC31518COV3001 | Covid Vaccine | Janssen | ♂+♀
≥18 and ≤60 & ≥60 |
306 | 2020 – 2022 | |
| 12 | Crown Coronation Study | Covid PrEP | WRHI | ♂+♀
≥18 and ≤60 & ≥60 |
60 | 2020 – 2021 | |
| 13 | HVTN 405 | Covid observational | CoVPN | ♂/♀ ≥18 | target 15 | 2020 – 2021 | |
| 14 | CoVPN5001 / HVTN5001 | Covid observational | CoVPN | ♂+♀ ≥18 | Target 15 | 2020 – 2021 | |
| 15 | The CARE Project | Behavioural Study | DSI NRF | Surveys | Target 100 | 2021 | |
| 16 | ACTIV-2 A5401 | COVID IV Infusion | PPD | ♂+♀ ≥18 | Target 75 | 2021 – 2022 | |
| 17 | 212171 (RSV MAT-009) | RSV Vaccine | GSK | ♀ 18 – 49 | Target 250 | 2021 – 2023 |
OUR EXPERIENCE
COVID-19
Areas of Expertise
Completed Projects
Current Projects